Janus Henderson Group Ltd. filed Amendment No. 11 to its Schedule 13G with the SEC on November 16, 2026, disclosing a beneficial ownership position in Mirum Pharmaceuticals, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Janus Henderson Group Ltd. reported beneficial ownership of 5,537,330 shares of Mirum Pharmaceuticals, Inc. common stock.
  • Percent of class: The 5,537,330 shares represent 8.5% of the outstanding class, according to the filing.
  • No sole voting or dispositive power: The filing discloses 0 shares held with sole voting power and 0 shares held with sole dispositive power.
  • Shared power: All 5,537,330 shares are reported under both shared voting power and shared dispositive power.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.
  • No single managed portfolio exceeds 5%: According to the filing, none of the Managed Portfolios individually owns more than five percent of the common stock of Mirum Pharmaceuticals, Inc.

Janus Henderson's Amendment 11 Position in Mirum Pharmaceuticals Common Stock

Janus Henderson Group Ltd., organized in Jersey and headquartered at 201 Bishopsgate, EC2M 3AE, United Kingdom, filed this Schedule 13G amendment as a parent holding company (type "HC") covering its beneficial interest in common stock of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), whose principal offices are located at 989 East Hillsdale Boulevard, Suite 300, Foster City, CA 94404. The filing covers shares with CUSIP number 604749101.

According to the filing, Janus Henderson Group Ltd. is the ultimate parent of multiple SEC-registered investment advisers and foreign equivalents, including Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Victory Park Capital Advisors LLC, and Richard Bernstein Advisors LLC, among others collectively referred to as the "Asset Managers." The filing states that "the Asset Managers generally exercise investment and/or voting discretion on behalf of their clients," which include investment companies, institutional separate accounts, and retail separate accounts, collectively described as "Managed Portfolios." As a result of this discretion, the Asset Managers "may be deemed to be the beneficial owner of 5,537,330 common stock of Mirum Pharmaceuticals, Inc."

The filing further notes that the Asset Managers "do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights." Instead, the Managed Portfolios retain the right to receive dividends and sale proceeds from the securities in their respective accounts. The filing also states, consistent with the certification required under Schedule 13G, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing was signed by Kristin Mariani, Head of North America Compliance, on November 16, 2026.

What Was Disclosed

Janus Henderson Group Ltd. disclosed, via Amendment No. 11 to Schedule 13G, that it beneficially owns 5,537,330 shares, or 8.5%, of Mirum Pharmaceuticals, Inc. common stock as of September 30, 2026, with all shares held under shared voting and dispositive power through its Asset Managers.